Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VYNE Therapeutics Inc. (MNLO)
|
Add to portfolio |
|
|
|
| Price: |
$1.15
| | Metrics |
| OS: |
3.28
|
M
| |
-203
|
% ROE
|
| Market cap: |
$3.77
|
M
| |
|
|
|
Net cash:
|
$20.6
|
M
| |
$6.29
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($33.8)
|
M
| |
|
|
|
EBIT
|
($33.8)
|
M
| |
|
|
| EPS |
($7.37)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.5 | 0.9 | 21.0 | 0.4 | 3.6 | 4.6 | 0.7 | 0.0 |
| Revenue growth | -48.8% | -95.6% | 4638.8% | -87.7% | -21.5% | 579.8% | | |
| Cost of goods sold | 0.3 | 0.1 | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.2 | 0.8 | 19.6 | 0.4 | 3.6 | 4.6 | 0.7 | 0.0 |
| Gross margin | 40.9% | 90.0% | 93.4% | 95.9% | 98.8% | 100.0% | 100.0% | |
| Selling, general and administrative | 16.4 | 20.3 | 89.5 | 45.1 | 14.0 | | | |
| Research and development | 18.4 | 19.5 | 43.5 | 51.2 | 64.5 | 29.0 | 11.3 | 2.9 |
| General and administrative | | | | | | 5.2 | 3.8 | 1.7 |
| EBIT | -34.6 | -39.0 | -200.3 | -95.9 | -74.9 | -29.6 | -14.3 | -4.6 |
| EBIT margin | -7248.8% | -4189.5% | -954.1% | -21645.8% | -2084.5% | -645.9% | -2126.4% | |
| Pre-tax income | -33.9 | -44.7 | 255.8 | 95.4 | 74.0 | -29.1 | -14.1 | -4.6 |
| Income taxes | 0.0 | -0.4 | 0.3 | 0.2 | -0.2 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 1.0% | 0.1% | 0.2% | | 0.0% | 0.0% | 0.0% |
| Net income | -23.2 | -73.3 | 255.6 | 95.2 | 74.2 | -29.1 | -14.1 | -4.6 |
| Net margin | -4863.7% | -7876.4% | 1217.4% | 21484.9% | 2062.9% | -634.6% | -2087.2% | |
| |
| Diluted EPS | ($10.64) | ($15.46) | $7.88 | $11.22 | $11.47 | ($5.69) | ($2.82) | ($0.97) |
| Shares outstanding (diluted) | 3.2 | 2.9 | 32.4 | 8.5 | 6.5 | 5.1 | 5.0 | 4.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|